Bridge City Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History

Bridge City Capital, LLC

$371 Million
Q4 2024

A detailed history of Bridge City Capital, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridge City Capital, LLC holds 94,997 shares of SUPN stock, worth $3.05 Million. This represents 0.93% of its overall portfolio holdings.

Number of Shares

94,997

Previous 94,236 0.81%

Holding current value

$3.05 Million

Previous $2.94 Million 16.92%

% of portfolio

0.93%

Previous 0.82%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$31.89 - $37.83 $24,268 - $28,788	761 Added 0.81%	94,997 $3.44 Million
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $307,977 - $420,197	11,951 Added 14.52%	94,236 $2.94 Million
Q2 2024 Aug 12, 2024	BUY	$25.99 - $33.85 $42,233 - $55,006	1,625 Added 2.01%	82,285 $2.2 Million
Q1 2024 Apr 12, 2024	BUY	$27.11 - $35.17 $53,813 - $69,812	1,985 Added 2.52%	80,660 $2.75 Million
Q4 2023 Feb 13, 2024	BUY	$22.72 - $29.68 $303,948 - $397,059	13,378 Added 20.49%	78,675 $2.28 Million
Q3 2023 Nov 15, 2023	BUY	$27.57 - $32.91 $68,070 - $81,254	2,469 Added 3.93%	65,297 $1.8 Million
Q2 2023 Aug 16, 2023	BUY	$29.91 - $38.73 $1,136 - $1,471	38 Added 0.06%	62,828 $1.89 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $8,033 - $9,666	-230 Reduced 0.36%	62,790 $2.27 Million
Q4 2022 Jan 25, 2023	SELL	$31.09 - $37.88 $13,928 - $16,970	-448 Reduced 0.71%	63,020 $2.25 Million
Q3 2022 Nov 08, 2022	BUY	$28.79 - $35.41 $60,919 - $74,927	2,116 Added 3.45%	63,468 $2.15 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $2,760 - $3,733	-109 Reduced 0.18%	61,352 $1.77 Million
Q1 2022 May 18, 2022	SELL	$28.51 - $32.9 $1.35 Million - $1.56 Million	-47,401 Reduced 43.54%	61,461 $1.99 Million
Q4 2021 Jan 20, 2022	SELL	$26.37 - $34.22 $580 - $752	-22 Reduced 0.02%	108,862 $3.17 Million
Q3 2021 Nov 10, 2021	SELL	$23.54 - $31.39 $680,258 - $907,108	-28,898 Reduced 20.97%	108,884 $2.9 Million
Q2 2021 Aug 11, 2021	SELL	$26.72 - $33.19 $122,404 - $152,043	-4,581 Reduced 3.22%	137,782 $4.24 Million
Q1 2021 Apr 28, 2021	SELL	$24.15 - $31.45 $35,017 - $45,602	-1,450 Reduced 1.01%	142,363 $3.73 Million
Q4 2020 Feb 12, 2021	SELL	$17.7 - $25.81 $26,479 - $38,611	-1,496 Reduced 1.03%	143,813 $3.62 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $435,007 - $539,451	21,535 Added 17.4%	145,309 $3.03 Million
Q2 2020 Jul 15, 2020	BUY	$17.09 - $24.89 $22,063 - $32,132	1,291 Added 1.05%	123,774 $2.94 Million
Q1 2020 May 11, 2020	BUY	$14.45 - $24.69 $206,418 - $352,696	14,285 Added 13.2%	122,483 $2.2 Million
Q4 2019 Jan 28, 2020	BUY	$19.93 - $29.13 $400,034 - $584,697	20,072 Added 22.78%	108,198 $2.57 Million
Q3 2019 Oct 22, 2019	BUY	$25.47 - $33.37 $487,139 - $638,234	19,126 Added 27.72%	88,126 $2.42 Million
Q2 2019 Jul 25, 2019	BUY	$29.96 - $38.87 $10,126 - $13,138	338 Added 0.49%	69,000 $2.28 Million
Q1 2019 Apr 30, 2019	BUY	$32.77 - $41.99 $565,479 - $724,579	17,256 Added 33.57%	68,662 $2.41 Million
Q4 2018 Jan 30, 2019	BUY	$30.84 - $49.51 $171,562 - $275,424	5,563 Added 12.13%	51,406 $1.71 Million
Q3 2018 Oct 25, 2018	SELL	$42.7 - $56.55 $83,350 - $110,385	-1,952 Reduced 4.08%	45,843 $2.31 Million
Q2 2018 Jul 23, 2018	SELL	$44.1 - $59.85 $70,339 - $95,460	-1,595 Reduced 3.23%	47,795 $2.86 Million
Q1 2018 Apr 26, 2018	BUY	$37.15 - $46.9 $111,264 - $140,465	2,995 Added 6.46%	49,390 $2.26 Million
Q3 2017 Oct 30, 2017	BUY	$36.75 - $49.65 $1.71 Million - $2.3 Million	46,395	46,395 $1.86 Million

Others Institutions Holding SUPN

# of Institutions

303

Shares Held

60.6M

Call Options Held

22.3K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.72B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridge City Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridge City Capital, LLC with notifications on news.

Account

Bridge City Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History